GSK Stock Forecast for 2023 - 2025 - 2030
Updated on 02/05/2023
GSK Stock Forecast and Price Target
The average price target of £16.10 for GSK's stock set by sixteen distinguished analysts in recent weeks would represent a potential downside of approximately -98.88% from the last closing price in February, 2023 if reached by the end of the year. This potential increase is based on a high estimate of £25.70 and a low estimate of £11.10. If you are not interested in GSK stock, you may be interested in its competitors.
-98.88% Downside
GSK Fair Value Forecast for 2023 - 2025 - 2030
GSK's Price has decreased In the last two years, from £15.83 to £14.50 – a 8.39% drop. In the next year, analysts believe that Fair Value will reach £15.04 – an increase of 3.71%. For the next nine years, the forecast is for Fair Value to grow by 3.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$145.20 | Buy/Sell | $162.12 | 13.64% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
8
|
£10.58k | Buy/Sell | £153.20 | -98.53% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$111.79 | Buy/Sell | $120.97 | 11.82% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$74.45 | Buy/Sell | $80.99 | 11.48% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$245.17 | Buy/Sell | $268.00 | 13.39% |
GSK Revenue Forecast for 2023 - 2025 - 2030
In the last two years, GSK's Revenue has grown, rising from £33.75B to £34.11B – a growth of 1.07%. In the following year, 0 experts forecast GSK's Revenue will decrease by 0.36%, to £33.99B. In 2030, professionals predict that GSK's Revenue will decrease by 0.34%, to £34.00B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$84.50 | Buy/Sell | $87.30 | 4.14% |
| CSL Stock Forecast | CSL | Outperform |
8
|
$313.81 | Buy/Sell | $218.60 | -27.96% |
| BDX Stock Forecast | Becton, Dickinson and | Outperform |
17
|
$245.84 | Buy/Sell | $268.00 | 11.86% |
.jpg)
GSK Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, GSK's Dividend per Share has seen a drop from £1.00 to £1.00 – a 0.00% decrease. According to 0 major analysts, GSK's Dividend per Share will fall by 0.00% in the next year, reaching £1.00. Professionals believe that By 2030, GSK's Dividend per Share will fall to £1.00– a 0.00% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
16
|
$117.49 | Buy/Sell | $147.79 | 1.71% |
| CL Stock Forecast | Colgate-Palmolive Co | Outperform |
18
|
$74.29 | Buy/Sell | $81.35 | 10.38% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | Buy/Sell | ¥0.00 | 35.30% |
GSK Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, GSK's Free Cash Flow has grown by 0.37%, rising from £6.76B to £6.78B. For the next year, analysts predict that Free Cash Flow will reach £6.91B – an increase of 1.94%. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 1.98%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAYN Stock Forecast | Bayer | Outperform |
7
|
56.68€ | Buy/Sell | 74.54€ | 33.20% |
| ADM Stock Forecast | Archer-Daniels-Midland | Outperform |
4
|
$82.28 | Buy/Sell | $99.07 | 20.32% |
| CTVA Stock Forecast | Corteva Inc | Outperform |
12
|
$61.50 | Buy/Sell | $73.12 | 18.70% |
GSK Net Income Forecast for 2023 - 2025 - 2030
In the last two years, GSK's Net Income has gone down from £4.65B to £4.39B – a 5.60% drop. In the next year, analysts believe that Net Income will reach £5.01B – an increase of 14.34%. For the next nine years, the forecast is for Net Income to grow by 15.20%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$154.55 | Buy/Sell | $162.50 | 7.73% |
| ABEV3 Stock Forecast | Ambev | Outperform |
18
|
R$12.98 | Buy/Sell | R$17.02 | 32.90% |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
18
|
¥3.31k | Buy/Sell | ¥0.00 | 36.03% |
GSK EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, GSK's EBITDA has decreased from £10.32B to £9.91B – a 4.03% drop. In the next year, analysts predict that EBITDA will jump to £10.18B – up 2.80% from the current level. Looking ahead to nine years, experts forecast that EBITDA will grow by 2.75%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF66.18 | Buy/Sell | CHF0.00 | 30.51% |
| BN Stock Forecast | Danone | Hold |
18
|
49.65€ | Buy/Sell | 55.47€ | 11.78% |
| HEN3 Stock Forecast | Henkel AG & Co. KGaA | Hold |
16
|
65.62€ | Buy/Sell | 66.02€ | 1.34% |
GSK EBIT Forecast for 2023 - 2025 - 2030
In the last two years, GSK's EBIT has decreased by 2.87%, going from £8.20B to £7.97B. Analysts predict that GSK's EBIT will increase in the upcoming year, reaching £8.21B. This would represent an increase of 3.00%. Over the next nine years, experts predict that GSK's EBIT will grow at a rate of 2.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.92k | Buy/Sell | ¥0.00 | 24.74% |
| BEI Stock Forecast | Beiersdorf | Outperform |
17
|
112.45€ | Buy/Sell | 110.36€ | 2.27% |
| COLO B Stock Forecast | Coloplast A/S | Hold |
18
|
kr848.20 | Buy/Sell | kr1.05k | 21.43% |
GSK EPS Price Prediction Forecast for 2023 - 2025 - 2030
GSK's EPS has decreased In the last two years, from £1.55 to £1.42 – a 8.39% drop. In the next year, analysts believe that EPS will reach £1.47 – an increase of 3.71%. For the next nine years, the forecast is for EPS to grow by 3.58%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| HOLX Stock Forecast | Hologic Inc | Outperform |
8
|
$84.68 | Buy/Sell | $79.86 | -2.57% |
| 4523 Stock Forecast | Eisai | Hold |
18
|
¥8.15k | Buy/Sell | ¥0.00 | -18.99% |
| CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$82.90 | Buy/Sell | $82.17 | 2.53% |
.jpg)